Please ensure Javascript is enabled for purposes of website accessibility

Melissa Mitchell

Melissa Mitchell is an Intellectual Property Attorney in the Biotechnology & Chemical Practice Group. Melissa earned a Bachelor of Science in Biological Sciences from Mississippi State University followed by a Master of Science in Biomedical Science from the University of Mississippi Medical Center. Melissa’s practice primarily relates to the preparation and prosecution of biotechnology, chemical, and plant patents.

Melissa attended Washington University School of Law and graduated in 2021. While in law school, Melissa was a staff member of the Washington University Jurisprudence Review and a board member of the WashU Intellectual Property Law Association. Melissa also gained valuable experience in the Washington University Entrepreneurship & Intellectual Property Clinic.

  • Biotechnology Patents
  • Chemical Patents
  • Design Patents
  • Trademarks
  • Academic Research and Technology Transfer
  • Agritech
  • Animal Health
  • Chemistry, Material Sciences, and Nanotechnology
  • Food and Beverage Technologies
  • Medical Devices
  • Pharma and Nutra
  • Plant Breeding and Plant-Related Technology

Iowa State Bar Association

Iowa Intellectual Property Law Association

Washington University in St. Louis School of Law, J.D., 2021

University of Mississippi Medical Center, M.S., Biomedical Science, 2017

Mississippi State University, B.S., Biological Sciences, 2013

Publications

A Match Made in Antitrust Heaven? A Liberalistic Exploration of the Medical Match’s Antitrust Exemption, 13 Wash. U. Juris. Rev. 121 (2020).

Iowa State Bar, 2021

U.S. Patent & Trademark Office, 2020

Washington University Jurisprudence Review, Notes Editor

CALI Excellence for the Future Award – Legal Practice I

USPTO Extends Cancer Immunotherapy Pilot Program

The United States Patent and Trademark Office recently issued a notice extending the Cancer Immunotherapy Pilot Program (AKA “Patents 4 Patients”) until September 30, 2022. The program was first implemented in 2016 as part of the $1 billion National Cancer Moonshot initiative and allows for fast-track review of cancer immunotherapy-related patent applications without the need […]

Read Post →

Stay in Touch

Receive the latest news and updates from us and our attorneys.

Sign Up